Levetiracetam Mylan

Levetiracetam, the active ingredient in Levetiracetam Mylan, is an Anticonvulsant presented as a tablet for oral use. It is employed to control various types of epileptic seizures, including partial, myoclonic and primary generalized tonic‑clonic seizures, in patients diagnosed with epilepsy across the European Union.

GNH USA supplies Levetiracetam Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity for global health care providers.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability to treat several seizure types.

- Partial seizures: reduces frequency of focal onset seizures in patients with epilepsy. - Myoclonic seizures: decreases occurrence of sudden, brief muscle jerks associated with myoclonic epilepsy. - Primary generalized tonic‑clonic seizures: helps prevent convulsive seizures that involve the whole brain.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Irritability - Headache - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Severe skin rash with blistering - Blood dyscrasias such as neutropenia or thrombocytopenia - Multi‑organ hypersensitivity reactions

Before initiating therapy, consider the following precautions to ensure safe use of levetiracetam.

- Renal impairment: dose may need adjustment based on creatinine clearance. - Pregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional. - Breastfeeding: unknown excretion in milk; evaluate necessity of treatment versus infant exposure. - Psychiatric symptoms: monitor for mood changes, depression, or agitation. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, decreasing levetiracetam plasma levels. - Phenobarbital: enzyme induction leading to reduced levetiracetam exposure. - Phenytoin: increases clearance of levetiracetam, potentially lowering effectiveness. - Rifampin: strong inducer that may markedly lower levetiracetam concentrations. - St. John’s wort: herbal inducer that can reduce levetiracetam levels.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase sedation. - Other antiepileptics (e.g., valproate): may require dose adjustments. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, consider alternative contraception. - Antidepressants (e.g., SSRIs): monitor for increased irritability or mood changes. - NSAIDs: observe for any change in seizure control or side‑effect profile.